Promote Sign in Sign up

Translation

floatz AI

AI for Drug Discovery, surfaces high-potential drug targets.

Source rating 5.0 (65) 180 views 180/mo traffic 0 saves Unknown
AI Drug discovery Target Identification
More categories (8)
Biotechnology Genetics Omics Pathway Analysis Drug Development R&D Life sciences Therapeutic Targets
Visit website Sign in to save

Verdict

A quick read before you dig into the full page.

Best if
AI for Drug Discovery, surfaces high-potential drug targets
Pick this when
AI for Drug Discovery, surfaces high-potential drug targets

Overview

floatz AI for Drug Discovery helps surface high-potential drug targets grounded in human genetics, expression patterns, and biological pathways, built for translational success. It integrates human genetics, tissue expression, and pathway analysis to map billions of concepts and identify targets with real translational potential, delivering 3 clinically-relevant targets in 14 days.

floatz AI screenshot

Access & connections

Where you can use floatz AI.

Platforms

Web

Capabilities

What this tool accepts, produces, and is strongest at.

Highlights

  • AI-driven drug target identification
  • Integration of human genetics, tissue expression, and pathway analysis
  • Delivery of 3 clinically-relevant targets in 14 days
  • Multi-layered analysis (literature, omics, disease biology, competitive intelligence)
  • Expert-reviewed target selection

FAQ 11

What is floatz?
floatz AI for Drug Discovery helps surface high-potential drug targets grounded in human genetics, expression patterns, and biological pathways, built for translational success. It integrates human genetics, tissue expression, and pathway analysis to map billions of concepts and identify targets with real translational potential, delivering 3 clinically-relevant targets in 14 days.
How to use floatz?
Users define their strategic focus (therapeutic area, indication, constraints). floatz then analyzes the opportunity space by combining literature, disease biology, omics data, pathway networks, and competitive intelligence. Finally, floatz curates and shortlists three high-potential targets, providing scientific rationale, referenced data, and expert review in a decision-ready PDF brief within 14 days.
Who is this for?
Early-stage biotechs, R&D leaders, or innovation teams looking to explore novel targets for a specific disease area — without months of internal work.
How are the targets selected?
We combine literature-derived signals, disease biology, omics, and competitive data — then filter for novelty, relevance, and druggability. Final selection is expert-reviewed.
Will our request remain confidential?
Yes. We do not share, reuse, or disclose your disease focus or brief content. All briefs are client-specific.
What if we’re not satisfied with the brief?
If the brief doesn’t meet expectations, we apply your full payment toward a revised version.
Do we get exclusive access to the targets?
Yes — your brief is created specifically for your request and is not shared or reused across clients. Each brief is handcrafted based on your disease area and constraints. We do not recycle targets or resell previously delivered content.
What’s included in the brief?
A shortlist of 3 targets, each with rationale, references, novelty and tractability insights — delivered in PDF format, decision-ready.
How long does it take?
14 days from scope confirmation. If we can’t deliver, you don’t pay.
Can we request specific constraints or focus (e.g., modality)?
Yes. We welcome constraint inputs to align with your pipeline or platform capabilities.
Can we talk before committing?
Yes — reach out if you’d like to align before submitting a brief request.
floatz AI
Visit website